Rhythm Pharmaceuticals
RYTM
84 hedge funds and large institutions have $741M invested in Rhythm Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
8.57% more ownership
Funds ownership: 90.81% → 99.38% (+8.6%)
8% more capital invested
Capital invested by funds: $688M → $741M (+$52.9M)
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0% more funds holding
Funds holding: 84 → 84 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$42.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$33M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$12.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.3M |
| 5 |
Primecap Management
Pasadena,
California
|
+$5.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$17.3M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$12.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.79M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.04M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.91M |
RYTM Hedge Fund Activity: Q3 2019 in Review
84 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2019, worth a combined $741M — up 7.7% from $688M a quarter earlier.
Fund positioning in RYTM was balanced in Q3 2019: 14 funds opened new positions, 14 closed out, 28 added to existing stakes and 26 trimmed.
The largest buyer was Deerfield Management, adding an estimated $42.2M. The largest seller was OrbiMed, exiting entirely with an estimated $17.3M sold.
- 84 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $741M of Rhythm Pharmaceuticals stock for Q3 2019, up 7.7% quarter-over-quarter.
- 14 funds opened new Rhythm Pharmaceuticals positions in Q3 2019 and 14 closed out, a net change of 0 holders.
- The largest Rhythm Pharmaceuticals buyer in Q3 2019 was Deerfield Management, an estimated $42.2M added.
- The largest Rhythm Pharmaceuticals seller in Q3 2019 was OrbiMed, an estimated $17.3M sold.
Based on aggregated 13F filings for Q3 2019.